| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Regeneron Pharmaceuticals, Inc., Tarrytown, NY.
Address correspondence and reprint requests to Dr. Jesse M. Cedarbaum, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd., Tarrytown, NY 10591.
We analyzed data from the 245-patient placebo group of the ALS CNTF Treatment Study Group study, a large, prospective, multicenter study of recombinant human ciliary neurotrophic factor to determine prognostic factors for length of survival in ALS. Variables examined included baseline demographic characteristics, indices of disease severity, pulmonary function, and clinical laboratory tests. Shorter survival was associated with greater age, lower percent-predicted forced vital capacity (FVC%), and lower serum chloride at study entry. A shorter interval from symptom onset to diagnosis of ALS and greater weight loss in the 2 months before study entry also predicted shortened survival times. The rate of muscle strength loss before study entry did not predict risk of mortality. Serum chloride, reflecting the degree of respiratory acidosis, was identified for the first time as being correlated with prognosis in ALS. The relationship between a patient's FVC% and the probability of survival is described.
*See the Appendix on page 71 for a list of ALS CNTF Treatment Study Group members.
Supported entirely by a grant from Regeneron Pharmaceuticals.
Presented in part at the 48th Annual Meeting of the American Academy of Neurology, San Francisco, CA, March 1996.
Received February 15, 1997. Accepted in final form August 8, 1997.
This article has been cited by other articles:
|
|
 |
|
  R. Miller, W. Bradley, M. Cudkowicz, J. Hubble, V. Meininger, H. Mitsumoto, D. Moore, H. Pohlmann, D. Sauer, V. Silani, et al. Phase II/III randomized trial of TCH346 in patients with ALS Neurology, August 21, 2007; 69(8): 776 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Shoesmith, K. Findlater, A. Rowe, and M. J Strong Prognosis of amyotrophic lateral sclerosis with respiratory onset J. Neurol. Neurosurg. Psychiatry, June 1, 2007; 78(6): 629 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Visser, R. M. van den Berg-Vos, H. Franssen, L. H. van den Berg, J. H. Wokke, J. M. Vianney de Jong, R. Holman, R. J. de Haan, and M. de Visser Disease Course and Prognostic Factors of Progressive Muscular Atrophy Arch Neurol, April 1, 2007; 64(4): 522 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Czaplinski, L. J. Haverkamp, A. A. Yen, E. P. Simpson, E. C. Lai, and S. H. Appel The value of database controls in pilot or futility studies in ALS Neurology, November 28, 2006; 67(10): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kalra, A Vitale, N R Cashman, A Genge, and D L Arnold Cerebral degeneration predicts survival in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1253 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Carvalho and M. Swash Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol, April 1, 2006; 63(4): 557 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Czaplinski, A A Yen, and S H Appel Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 390 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Morgan, S. McNally, M. Alexander, R. Conroy, O. Hardiman, and R. W. Costello Use of Sniff Nasal-Inspiratory Force to Predict Survival in Amyotrophic Lateral Sclerosis Am. J. Respir. Crit. Care Med., February 1, 2005; 171(3): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Wilson, M. A. Quantz, M. J. Strong, and D. Ahmad Increasing Peak Expiratory Flow Time in Amyotrophic Lateral Sclerosis Chest, January 1, 2005; 127(1): 156 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P N Leigh, S Abrahams, A Al-Chalabi, M-A Ampong, L H Goldstein, J Johnson, R Lyall, J Moxham, N Mustfa, A Rio, et al. The management of motor neurone disease J. Neurol. Neurosurg. Psychiatry, December 1, 2003; 74(90004): iv32 - 47. [Full Text] [PDF]
|
|
|
|
|
|
F. Laghi and M. J. Tobin Disorders of the Respiratory Muscles Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 10 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. del Aguila, W.T. Longstreth Jr, V. McGuire, T.D. Koepsell, and G. van Belle Prognosis in amyotrophic lateral sclerosis: A population-based study Neurology, March 11, 2003; 60(5): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Howard and R W Orrell Management of motor neurone disease Postgrad. Med. J., December 1, 2002; 78(926): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M D Bradley, R W Orrell, J Clarke, A C Davidson, A J Williams, D M Kullmann, N Hirsch, and R S Howard Outcome of ventilatory support for acute respiratory failure in motor neurone disease J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(6): 752 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.B. Chaudri, C. Liu, R. Hubbard, D. Jefferson, and W.J. Kinnear Relationship between supramaximal flow during cough and mortality in motor neurone disease Eur. Respir. J., March 1, 2002; 19(3): 434 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lyall, N. Donaldson, M. I. Polkey, P. N. Leigh, and J. Moxham Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis Brain, October 1, 2001; 124(10): 2000 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hadjikoutis and C.M. Wiles Venous serum chloride and bicarbonate measurements in the evaluation of respiratory function in motor neuron disease QJM, September 1, 2001; 94(9): 491 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Miller, J. A. Rosenberg, D. E. Gelinas, H. Mitsumoto, D. Newman, R. L. Sufit, G. D. Borasio, W. G. Bradley, M. B. Bromberg, B. R. Brooks, et al. Practice Parameter: The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurorehabil Neural Repair, June 1, 1999; 13(2): 93 - 107. [PDF]
|
|
|
|
|
|
R. G. Miller, J. A. Rosenberg, D. F. Gelinas, H. Mitsumoto, D. Newman, R. Sufit, G. D. Borasio, W. G. Bradley, M. B. Bromberg, B. R. Brooks, et al. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, April 1, 1999; 52(7): 1311 - 1311. [Full Text] [PDF]
|
|
|
|
|
|
A controlled trial of recombinant methionyl human BDNF in ALS Neurology, April 1, 1999; 52(7): 1427 - 1427. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
